Fri, May 28, 2010 page2

• Local doctor inspires Harrison Ford film

  • STAFF WRITER, WITH CNA
  • • 
    • 
    • 

  The movie Extraordinary Measures tells the story of parents who formed a biotechnology company to develop a drug that could save the lives of children who have the rare life-threatening disease known as Pompe.

  In the movie, which is based on the book The Cure, Harrison Ford plays research scientist Robert Stonehill, who was instrumental in finding the cure, while Brendan Fraser plays John Crowley, the man who raised US$100 million to buck the medical establishment.

  In reality, John Crowley is the name of the person who started the biomedical company, but the real Dr Stonehill who developed the cure is in fact Chen Yuan-tsong (陳垣崇), director of Academia Sinica’s Institute of Biomedical Sciences.

  

  A girl with the rare Pompe disease presents a bouquet of flowers to Chen Yuan-tsong, director of Academia Sinica’s Institute of Biomedical Sciences, on Monday. Chen is the real person behind the character played by Harrison Ford in the Hollywood movie ­Extraordinary Measures.

  PHOTO: CNA

  At an event held earlier this week by the Taiwan Foundation for Rare Disorders to mark the debut in Taiwan of the movie’s DVD, Chen said he had mixed feelings watching the movie.

  He said he began researching a cure for Pompe disease in 1991 after being saddened by the deaths of so many children from the affliction.

  “Before I knew it, it had been 15 years,” he said. “It also surprised me that Hollywood would have made a motion picture out of it, making it the second movie about rare diseases and patients after Lorenzo’s Oil.”

  Movie critic Roger Ebert said that Harrison Ford, as the film’s executive producer, probably saw Stonehill as a good role for himself and ordered a rewrite of the script because he could not play Chen.

  Regardless of how Hollywood decided to recast Chen, his contribution to helping find the cure is well established.

  He developed the treatment with colleagues at the Duke University Medical Center. His research and development was mostly done in the US, but Chen conducted his clinical trials for the cure — later named Myozyme — at National Taiwan University Hospital.

  Myozyme, which took Chen and his team 15 years to research and develop, was introduced in Taiwan by US pharmaceutical company Genzyme and has been covered by the National Health Insurance (NHI) program since 2005, the foundation said.

  Myozyme was sold in Europe and the US after it was approved by the US Food and Drug Administration and the EU health authority in 2006. It has contributed to saving the lives of more than 1,000 patients with Pompe disease, or acid maltase deficiency, worldwide each year, including 34 in Taiwan.

  Young Pompe disease sufferers have symptoms similar to muscular dystrophy, the foundation said.

  Without a cure, most children with Pompe disease die before they reach two years old. There is also a juvenile and adult form of the disease, which can appear at almost any age, the foundation said.

  Currently, Pompe disease patients in Taiwan receive NT$7.9 million (US$245,577) per patient per year in Myozyme and related medical care under the NHI program, greatly reducing their families’ financial burden, the foundation said.

  The foundation quoted tallies from the Cabinet-level Department of Health as indicating that there are nearly 6,000 families with rare disease patients in Taiwan, but more than 70 percent of them do not receive effective drugs or therapies, the foundation said.
• Most Popular

  • 1

    Storm weakens, but warning still in force

  • 2

    MAC ‘fully aware’ of reports Bo Xilai’s son is in Taiwan

  • 3

    PRC threatens regional stability: Taipei

  • 4

    Taiwan to attend China APEC summit: official

  • 5

    APEC envoy invites Biden to Taiwan